儿童青少年精神科药物78项不良反应的大规模系统Meta综述
该系统Meta综述汇总了9项网络Meta分析、39项Meta分析、90项随机对照试验和8项队列研究,覆盖337,686名精神障碍儿童青少年,评估80种精神科药物(包括抗抑郁药、抗精神病药、抗ADHD药和心境稳定剂)的78项预设不良反应。艾司西酞普兰、氟西汀、鲁拉西酮、哌甲酯和锂的安全性相对较好,而文拉法辛、奥氮平、托莫西汀、胍法辛和丙戊酸的安全性最受关注。
要点
- 抗抑郁药最常与恶心呕吐及因不良反应停药相关,抗精神病药最常与镇静、锥体外系反应和体重增加相关。
- 抗ADHD药最常与厌食和失眠相关,心境稳定剂最常与镇静和体重增加相关。
- 文拉法辛、奥氮平、托莫西汀、胍法辛和丙戊酸的安全性最受关注。
核心结论
- 在数据覆盖至少20%的78项不良反应的药物中,抗抑郁药中艾司西酞普兰和氟西汀、抗精神病药中鲁拉西酮、抗ADHD药中哌甲酯、心境稳定剂中锂的安全性相对较好。
- 文献对文拉法辛、奥氮平、托莫西汀、胍法辛和丙戊酸的安全性关注最多。
研究设计与样本
- 系统检索网络Meta分析与Meta分析、随机对照试验及队列研究,纳入9项网络Meta分析、39项Meta分析、90项随机对照试验和8项队列研究。
- 共纳入337,686名患精神障碍的儿童青少年,评估80种精神科药物的78项预设不良反应,分属19类。
主要发现
- 抗抑郁药最常与恶心呕吐和因不良反应停药相关。
- 抗精神病药最常与镇静、锥体外系副作用和体重增加相关。
- 抗ADHD药最常与厌食和失眠相关;心境稳定剂最常与镇静和体重增加相关。
- 仅6种抗抑郁药、8种抗精神病药、3种抗ADHD药和2种心境稳定剂有至少20%的78项不良反应的数据。
关键数值与推荐
- 有至少20%的78项不良反应数据的药物:舍曲林、艾司西酞普兰、帕罗西汀、氟西汀、文拉法辛、维拉佐酮;利培酮、喹硫平、阿立哌唑、鲁拉西酮、帕利哌酮、齐拉西酮、奥氮平、阿塞那平;哌甲酯、托莫西汀、胍法辛;丙戊酸、锂。
- 安全性相对较好:艾司西酞普兰、氟西汀、鲁拉西酮、哌甲酯、锂。
- 最受关注:文拉法辛、奥氮平、托莫西汀、胍法辛、丙戊酸。
临床怎么用
- 可依据本综述的药物安全性特征,在儿童青少年用药选择与监测中权衡不良反应。
- 该证据可为临床实践、研究与治疗指南提供参考。
局限性
- 仅部分药物有至少20%的78项不良反应的数据,多数药物数据不足。
- 纳入研究以网络Meta分析、Meta分析、随机对照试验和队列研究为主,未报告其他设计证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mental disorders frequently begin in childhood or adolescence. Psychotropic medications have various indications for the treatment of mental dis-orders in this age group and are used not infrequently off-label. However, the adverse effects of these medications require special attention during developmentally sensitive periods of life. For this meta-review, we systematically searched network meta-analyses and meta-analyses of randomized controlled trials (RCTs), individual RCTs, and cohort studies reporting on 78 a priori selected adverse events across 19 categories of 80 psychotropic medications - including antidepressants, antipsychotics, anti-attention-deficit/hyperactivity disorder (ADHD) medications and mood stabilizers - in children and adolescents with mental disorders. We included data from nine network meta-analyses, 39 meta-analyses, 90 individual RCTs, and eight cohort studies, including 337,686 children and adolescents. Data on ≥20% of the 78 adverse events were available for six antidepressants (sertraline, escitalopram, paroxetine, fluoxetine, venlafaxine and vilazodone), eight antipsychotics (risperidone, quetiapine, aripiprazole, lurasidone, paliperidone, ziprasidone, olanzapine and asenapine), three anti-ADHD medications (methylphenidate, atomoxetine and guanfacine), and two mood stabilizers (valproate and lithium). Among these medications with data on ≥20% of the 78 adverse events, a safer profile emerged for escitalopram and fluoxetine among antidepressants, lurasidone for antipsychotics, methylphenidate among anti-ADHD medications, and lithium among mood stabilizers. The available literature raised most concerns about the safety of venlafaxine, olanzapine, atomoxetine, guanfacine and valproate. Nausea/vomiting and discontinuation due to adverse event were most frequently associated with antidepressants; sedation, extrapyramidal side effects, and weight gain with antipsychotics; anorexia and insomnia with anti-ADHD medications; sedation and weight gain with mood stabilizers. The results of this comprehensive and updated quantitative systematic meta-review of top-tier evidence regarding the safety of antidepressants, antipsychotics, anti-ADHD medications and mood stabilizers in children and adolescents can inform clinical practice, research and treatment guidelines.
引用
- Solmi M, Fornaro M, Ostinelli EG, et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. 2020. PMID: 32394557. doi:10.1002/wps.20765
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。